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Abstract
Purpose: To review the main clinical-radiographic, therapeutic, and preventive aspects of osteonecrosis related to 
intravenous bisphosphonate therapy in patients with multiple myeloma.
Materials and methods: Between 2005 and 2006, we studied four patients with previous diagnosis of multiple myeloma 
treated with intravenous zoledronic acid, presenting nonhealing extraction sockets and intraoral exposed bone. We 
assessed the location of lesions, the relation with previous history of dento-alveolar surgery procedures, the clinical 
features, the treatments carried out, and the outcomes achieved.
Results: All the patients were treated with chlorhexidine mouthwashes and oral amoxycilin-clavulanic acid for long 
periods of time. Two patients did not respond to the conservative management and needed surgical bone debride-
ment.
Conclusions: Dental extractions seem to contribute the development of osteonecrosis of the jaw in patients with 
multiple myeloma treated with intravenous bisphosphonate therapy. Whereas the pathologic mechanisms are not 
known, these patients should undergo frequent check-ups before, during, and after bisphosphonate therapy. The 
management must be symptomatic and palliative, including systemic antibiotics, control of pain, and chlorhexidine 
mouthwashes during long periods of time.
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Introduction
Bisphosphonates are drugs that inhibit bone resorption, 
indicated in the management of diverse diseases like multi-
ple myeloma (MM), bone metastasis caused by breast and 
prostate cancer, and the Paget´s disease, as well as to pre-
vent the osteoporosis in the menopause. In patients with 
MM, bisphosphonate therapy has improved the quality of 
life significantly because they are able to alleviate the pain 
and to reduce the development of skeletal complications. 
Since Marx (1) and Ruggiero et al. (2) in 2003 published 
the first patient series in which they associated the use of 
bisphosphonates with the appearance of exposed bone 
of the jaws in the oral cavity and the development of os-
teonecrosis, it had been published an increasing number 
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of  articles of  bisphosphonate-related to osteonecrosis 
(BRON) (3-5). Recently, the American Association of 
Oral and Maxillofacial Surgeons (6) has established 3 
characteristics that must be present to consider a BRON: 
(i) current or previous treatment with a bisphosphonate; 
(ii) exposed, necrotic bone in the maxillofacial region that 
has persisted for more than 8 weeks; and (iii) no history 
of radiation therapy of the jaws. Most of clinical cases 
reported have been related to the use of intravenous bis-
phosphonate (pamidronate or zoledronic acid), although 
it had been published some cases associated to oral bis-
phosphonate administration (7). The main risk factor for 
this complication is the previous history of dento-alveolar 
surgery, but it may appear spontaneous cases without 
previous trauma (3). The risk of developing a BRON in 
patients with MM seems to be time-dependent, and turns 
out to be significant after 36 months (8). Its incidence has 
not been completely established yet, although it has been 
reported an incidence of BRON in patients with MM of 
6.9% (9), 9.9% (10), and 10.93% (11). In a series of 25 
patients with BRON, Clarke et al. (12) found that an 80% 
of patients had a MM. 
The aim of this work has been to present our clinical 
and therapeutic experience on four patient diagnosed of 
BRON with previous history of MM attended during the 
last 2 years, focussing special consideration to clinical-
radiographic, therapeutic, and preventive features of this 
complication, describing a clinical case that developed a 
severe and progressive jaw osteonecrosis after previous 
dental extractions.
Material and methods
Between January 2005 and December 2006, 4 patients 
with nonhealing extraction sockets and exposed bone in 
the oral cavity have been attended in the Oral and Maxi-
llofacial Surgery Department of  the Virgen del Rocio 
University Hospital of  Seville, Spain. All the patients 
had been previously diagnosed of MM and treated with 
intravenous zoledronic acid. We studied the location of 
lesions, relation with previous history of dento-alveolar 
surgery procedures, symptoms and clinical features, 
treatments carried out, and outcomes achieved. All the 
patients underwent a panoramic x-ray and a CT scan. A 
bone gammagraphy was made in 1 patient. Biopsies were 
taken from bone areas in 3 patients. All the patients were 
initially treated with chlorhexidine mouthwashes and oral 
amoxycilin-clavulanic acid during long periods of time. 
2 patients did not respond to the conservative treatment 
and needed surgical treatment (Table 1).
Results
The patients consisted of 1 man and 3 women, with ages 
between 56 and 82 years (average age of 69.5 years). All 
the patients consulted by local pain. All the patients had 
exposed bone in the oral cavity and signs of local infec-
tion. One patient developed a cutaneous fistula that was 
treated with cefadroxil according to antibiogram, and 
analgesia with fentanyl and morphine. All the patients 
had previously received intravenous zoledronic acid. At 
diagnosis, 2 patients went on with bisphosphonate therapy. 
Only 1 patient continued the treatment with biphospho-
nate after BRON was diagnosed. Previous history of one 
or several dental extractions by dentists was detected in 
all the patients. Panoramic x-rays and TCs showed areas 
of bone necrosis that alternated radiopaque images with 
radiolucent areas, irregularities in the cortical bone, and 
affectation of the soft tissue. Histological studies informed 
of bone necrosis, inflammatory granulation tissue and 
abscessification. In the microbiological culture there were 
abundant bacterial colonies of saprophyte oral microbiota. 
In 1 patient klebiella pneumonie was isolated. In 3 patients 
the mandible was involved and in 1 patient the maxilla. 
One patient developed a para-mandibular abscess with 
extraoral cutaneous fistula (Table 1). 
Clinical case
A 56 years-old male was sent by a dentist in June 2005 
to evaluate “an infection of the mandible after a dental 
extractions, that after 3 months had not responded to 
treatment with antibiotics and previous bone debridation”. 
In his medical antecedents he emphasized that he had 
been diagnosed of a MM in 2001, and had been treated 
with chemotherapy, and submitted to a marrow bone 
autotransplant. He had a previous history of vertebrate 
fractures, and zoledronic acid intravenous administration 
in doses of 4 mg during 3 years. First and second right 
lowers molars had been extracted by a dentist in February 
2005. In the intraoral exploration 2 nonhealing extraction 
sockets were found, and the alveolar bone around was 
partially exposed (Figure 1A). The second premolar had 
mobility and acute pain to the percussion. In the panora-
mic x-ray the post-extraction socket tracks were seen, and 
a root of the first left molar remained in place (Figure 1B). 
Under local anaesthesia it was carried out the extraction 
of the root and the second premolar, and the debridement 
of a minimum necrotic bone; a biopsy was taken, and a 
microbiological culture was made. The histological study 
was informed as an “abscessificant osteomyelitis with 
central bone osteonecrosis”. The immuno-histochemis-
try study did not demonstrate concordant findings with 
myeloma (slight chain and CD-79 kappa and lambda 
negative). In the microbiological culture there were abun-
dant bacterial colonies without presence of Aspergillus. 
From these results, the BRON diagnosis was set down, 
and a oral hygiene conservative management with 0.12% 
chlorhexidine mouthwashes was established, antibiotic 
treatment 875/125 mg amoxycilin-clavulanic acid 3 times a 
day by oral administration during 4 weeks and nonesteroid 
anti-inflammatories. In the following 3 months, the patient 
evolved towards a clinical and radiographic improvement, 
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and the pain diminish almost completely although the soft 
tissue around the sockets had not healed. After consulting 
with the haematologist, the treatment with intravenous 
zoledronic acid was discontinued. 
In December 2005, the patient presented concerned with 
an intense local pain, although the clinical and radiogra-
phic exploration continued being anodyne. Treatment with 
nonesteroids anti-inflammatories, amoxycilin-clavulanic 
acid was restored again by oral administration. In spite 
of treatment, osteonecrosis continued progressing, and 
in February 2006 presented an exposed bone of 2x1 cm 
surrounded by an edge of reddened mucosa (Figure 2A). 
In the right sub-mandibular region appeared a soft tissue 
swelling with a purulent cutaneous fistula (Figure 2B), 
from where a microbiological culture was taken, isolating 
klebiella pneumonie, streptococcus sanguis and staphylo-
coccus epidermidis. In the panoramic x-ray bone necrosis 
had increased considerably showing a radiopaque image in 
the body of the mandible with radiolucent areas (Figure 
2C). In the CT scan multiple radiolucent areas were ob-
served along with areas of sclerosis in the body mandible 
of approximately 4 cm, with irregularities in cortical and 
the affectation of the soft tissues, subcutaneous fat edema, 
and thickening of the cutaneous plane (Figure 2D). The 
patient initiated treatment with oral cefadroxil 1 g twice a 
day according to the antibiogram, and for the control of 
the pain it was administrated fentanyl 75 mg in transdermis 
patches every 72h, and morphine sulphate 10 mg in tablets 
was indicated for pain rescue. During 2 months the patient 
continued the treatment with cefaxodril 1 g twice a day, 
pregabalin 150 mg twice a day, and 600 mg ibuprofen three 
times a day. In spite of clinical improvement, in May 2006 
a great bone area of sequestrum was delimited (Figure 
3A). The bone gammagraphy detected an increase of the 
tracer in the right body of the mandible (Figure 3B). Un-
der general anaesthesia bone sequestrums were debridated 
until apparently healthy bone. The outcome, although slow 
and torpid, has evolved to a significant improvement, and 
at this moment, 18 months after the initial diagnosis, our 
patient is asymptomatic and has no evidence of infection. 
In the panoramic x-ray, the image has been standardized, 
although intraoral soft tissue has not healed totally. The 
patient is followed in scheduled check-ups, and with rin-
sing of chlorhexidine mouthwashes.
Age 
(years) / 
Sex 
Location Risk factor Signs Exploration 
Radiological 
studies 
Discontinua- 
tion of 
bisphosphona
tes 
Treatment 
Outcome/ 
healing 
82/F Maxilla 
Teeth 
extractions Local pain 
Exposed 
bone 
Local 
infection 
OPG 
CT Yes 
Chlorhexid
ine 
Oral 
antibiotics 
Partial 
resolution 
 
56/M Mandible 
Teeth 
extractions 
Local pain 
Cutaneous 
fisutula 
Exposed 
bone 
Local 
infection 
OPG 
CT 
Gamma- 
graphy 
Yes 
Chlorhexid
ine 
Oral and 
IV 
antibiotics 
Surgical 
debrideme
nt 
Remaining 
exposed 
bone 
59/F Mandible 
Tooth 
extraction Local pain 
Exposed 
bone 
Local 
infection 
OPG 
CT No 
Chlorhexid
ine 
Oral 
antibiotics 
Partial 
resolution 
 
81/F Mandible 
Teeth 
extractions Local pain 
Exposed 
bone 
Local 
infection 
OPG 
CT Yes 
Chlorhexid
ine 
Oral and 
IV 
antibiotics 
Surgical 
debrideme
nt 
Small 
exposed area 
of bone 
Table 1. Characteristics of the 4 patients with MM, previous history of intravenous zoledronic acid treatment, and jaw osteonecrosis.
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Fig. 1. A y B. (A): Intraoral view of nonhealing sockets and mucosa around the 1º and 2º right lower molars, when the patient 
was sent 6 months after dental extractions, and (B): panoramic x-ray showing initial images of osteonecrosis. 
Fig. 3. A y B. (A): Sequestrum of bone 6 months after the start of conservative management. (B): Bone gammagraphy was com-
patible with bone infection.
Fig. 2. A-D. (A): Three months later appeared 
necrotic bone and mucosal inflammation and (B): 
soft tissue swelling and extraoral purulent fistula 
to the right sub-mandibular region. (C): The pano-
ramic x-ray showed a great area of osteolysis with 
sequestrums and bone necrosis. (D): In the CT scan 
a sclerosis area was observed in the mandible along 
with irregularities in cortical bone and affectation 
of soft tissues.
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Discussion
BRON is an exclusive affectation of jaws related to smaller 
bone traumas with a deficient healing, and to a vascularity 
compromised by the bisphosphonate, within the usual mi-
crobiological flora of the oral cavity (3,13). Some authors 
think that it takes place as a result of the direct influence of 
the bisphosphonate that inhibit osteclast cells that provoke 
bone resorption, and by the induction of the precursory 
osteoblast cells of the bone apposition. Also they restrain 
the bone calcium liberation induced by stimulating factors 
released by the tumor cells (14).
MM is a member of a neoplasm group with plasmatic 
cells that share two basic characteristics: the elevated 
production of  monoclonal antibodies and the loss of 
bone by osteolysis. Intravenous administrations of  zo-
ledronic acid and paminodrate have demonstrated that 
significantly reduce the skeletal complications in patients 
with MM (6). Nevertheless these patients have more risk 
to develop a BRON that patients with breast cancer which 
take bisphosphonate. The age seems to be a risk factor in 
patients with MM, because by every age decade the risk 
is increased in 9% (15). The average age of the patients 
of this series was almost 70 years old, two of them over 
80 years old.
The appearance of a BRON supposes an important dete-
rioration in the quality of life of a patient. It is located in 
the body of the mandible with more frequency, and it is 
characterized by the finding of exposed bone in the oral 
cavity, non-vital and that does not heal in 8-12 weeks (6). 
The symptoms usually are almost imperceptible or slight 
at the start, but with time they will be severe and causing 
extensive bone sequestrums, suppuration, and mucosa 
or cutaneous fistula, with continuous and intense pain. 
Ruggiero et al. (16) have proposed a classification in three 
clinical stages. Stage 1 is characterized by asymptomatic 
exposed necrotic bone. Stage 2 is characterized by necrotic 
bone exposed associated to pain, soft tissue inflammatory 
swelling or secondary infection. Stage 3 presents exposed 
necrotic bone associated to pain, soft tissue inflammatory 
swelling or secondary infection difficult to manage with 
oral or intravenous antibiotic administration, and the 
pathological presence of cutaneous fistula, bone fractures 
or great volume areas of necrosis that may require surgical 
treatment. The case described in this work presented these 
three evolutionary stages in the 18 months of follow-up.
For the diagnosis of BRON a radiological study of bone 
is required along with soft tissues. In early stages, radiolo-
gical studies may not show significant changes. In stages 
2 and 3, radiographies reveal images of osteolysis that 
normally extend beyond the area apparently affected, since 
the radiological images are only visible when a great part 
of mineralized bone is lost. These images determine the 
differential diagnosis with osteomyelitis, primary myeloma 
or bone metastasis disease. In most of severe cases are 
necessary studies of CT scan (17) or bone gammagraphy 
to establish the extension and affectation of  adjacent 
anatomical structures.
The best therapeutic strategy is the prevention of BRON 
setting up a program of oral and dental cares before, du-
ring and after bisphosphonate therapy that may reduce 
the complications. The beginning of the bisphosphonate 
therapy must be delayed until improving the oral hygiene, 
and the extraction of the badly teeth must be carried out 
one month before the start. Once initiated the adminis-
tration of the bisphosphonate, invasive dental treatments 
like the dental extractions must be limited, and the use 
of 0.12% chlorhexidine mouthwashes is advised. Calvo-
Villas et al. (11) question to prolong the treatment with 
zoledronic acid in patients with asymptomatic MM after 2 
years to avoid the BRNO risk. Nevertheless, discontinuing 
bisphosphonate therapy has not demonstrated a reduction 
in the BRON risk, since this drug has a long mean life 
and persists later in the human bone up to 10 years (16). 
Nevertheless, if  patient general conditions allow it, a long 
term discontinuation of the bisphosphonate therapy can 
be beneficial in stabilizing the progression of the osteo-
necrosis, reducing the risk of new areas of necrotic bone, 
and diminishing the symptoms (6), which  must done only 
after consulting with the oncologist or haematologist. We 
carried out it in 3 patients of our series.
The management of patients with an established diagnosis 
of BRON poses a therapeutic challenge. In stage 1, when 
BRNO is limited, a conservative nonsurgical treatment 
can be sufficient. It is recommended to intensify oral 
hygienic measures, to avoid the irritating factors, and to 
establish a long-term treatment with systemic antibiotics 
of wide spectrum and conventional nonesteroid anti-infla-
mmatories. When a purulent fistula is detected (stage 2), 
cultures and antibiogram should be carried out, although 
cultures are usually compatible with saprophita flora (17). 
The microbiological cultures are useful to select the best 
antibiotic to treat an infection, although antibiotics rarely 
obtain adequate concentrations due to their difficult access 
to bone because of the avascular bone necrosis (3).
In severe and progressive BRON in stage 3, a conservati-
ve treatment may be unsuccessful, as it happened in the 
clinical case presented in this work. Surgery is indicated 
when the conservative treatment have not worked out, or 
in lesions that show a progressive and symptomatic clinical 
course. When a surgical treatment is carried out (debride-
ment, bone sequestrectomy, bone resection), we have to 
consider that bone vascularization is compromised, and 
any surgical intervention although limited, can increase 
more exposed or necrotic bone areas, and besides can be a 
way of penetration of new micro-organisms. When remo-
ving mobile segments of bony sequestrums is needed, the 
smaller amount of uninvolved bone should be removed, 
and the less soft tissues should be manipulated (18). Other 
therapeutic alternatives like hyperbaric oxygen, recom-
mended in the management of  the osteoradionecrosis, 
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are not considered of utility in the ONRB (19). In many 
cases it is not achieved a completely control of exposed 
bone in spite of treatment, and the treatment should last 
during months or years, and that is why it is necessary to 
count on the collaboration of the patient
In summary, patients with MM that take intravenous 
bisphosphonate must be put under frequent scheduled 
check-ups to detect complications, during and after the 
treatment. Although does not exist a definitive manage-
ment for the ONRB, it must be symptomatic and pallia-
tive, including systemic antibiotics, control of the pain, 
and chlorhexidine mouthwashes during long periods of 
time. The aim of the management consists of preventing 
and decreasing the development or progression of bone 
necrosis, the control of the infection, and in alleviating 
the painful syntomatology.
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